18 criteria for choosing GSK's Cervarix
This article was originally published in Scrip
For those wondering how the department of health chose between GlaxoSmithKline's Cervarix and Sanofi Pasteur MSD's Gardasil for the UK's cervical cancer vaccine campaign (Scrip No 3373, p 1), health minister Dawn Primarolo has listed in a recent parliamentary answer the 18 criteria that were used. As well as the obvious clinical and cost reasons, the criteria include pallet configuration, the robustness of manufacturing contingency arrangements, the risk of wastage if subjected to temperatures above 8°C, and the closeness of delivery schedules to requirements.
You may also be interested in...
The UK’s Vectura plc is gaining value from its back catalog of novel compounds through licensing its pan-JAK inhibitor, VR588, to a US start-up, the venture capital-backed Kinaset Therapeutics.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
An upturn in M&A activity across the whole healthcare sector is expected in 2021, with the COVID-19 pandemic and the associated development of a vaccine shining a light on the sector, says a recent survey by Jefferies.